{"drugs":["Dificid","Fidaxomicin"],"mono":{"0":{"id":"929929-s-0","title":"Generic Names","mono":"Fidaxomicin"},"1":{"id":"929929-s-1","title":"Dosing and Indications","sub":[{"id":"929929-s-1-4","title":"Adult Dosing","mono":"<b>Clostridium difficile infection:<\/b> 200 mg ORALLY twice daily with or without food for 10 days "},{"id":"929929-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been studied in patients younger than 18 years of age "},{"id":"929929-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>gender:<\/b> no dose adjustment needed<\/li><li><b>geriatric:<\/b> no dose adjustment needed<\/li><li><b>renal:<\/b> no dose adjustment needed<\/li><\/ul>"},{"id":"929929-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Clostridium difficile infection<br\/>"}]},"3":{"id":"929929-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929929-s-3-9","title":"Contraindications","mono":"hypersensitivity to fidaxomicin or any product component <br\/>"},{"id":"929929-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity reaction, acute (ie, dyspnea, pruritus, rash, angioedema of the face, mouth, and throat) has occurred; increased risk with history of macrolide allergy; discontinue use if severe reaction develops<\/li><li>lack of confirmation or strongly suspected Clostridium difficile-associated diarrhea; increased risk of bacterial drug resistance<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929929-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"929929-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929929-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (6%), Nausea (11%), Vomiting (7%)<\/li><li><b>Hematologic:<\/b>Anemia (2%), Neutropenia (2%)<\/li><\/ul><b>Serious<\/b><br\/><b>Gastrointestinal:<\/b>Bowel obstruction (less than 2%), Gastrointestinal hemorrhage (4%)<br\/>"},"6":{"id":"929929-s-6","title":"Drug Name Info","sub":{"0":{"id":"929929-s-6-17","title":"US Trade Names","mono":"Dificid<br\/>"},"2":{"id":"929929-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"929929-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929929-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929929-s-7","title":"Mechanism Of Action","mono":"Fidaxomicin, a locally-acting macrolide antibiotic, is bactericidal via inhibition of RNA polymerases primarily against Clostridia species including Clostridium difficile <br\/>"},"8":{"id":"929929-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929929-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 2 hours<\/li><li>Bioavailability, Oral: minimal<\/li><li>Effect of food: AUC unchanged<\/li><\/ul>"},"2":{"id":"929929-s-8-25","title":"Metabolism","mono":"<ul><li>Intestine: primary site<\/li><li>OP-1118: active<\/li><\/ul>"},"3":{"id":"929929-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: more than 92% recovered changed and unchanged<\/li><li>Renal: 0.59% unchanged<\/li><\/ul>"},"4":{"id":"929929-s-8-27","title":"Elimination Half Life","mono":"11.7 hours <br\/>"}}},"9":{"id":"929929-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>may take with or without food <br\/>"},"10":{"id":"929929-s-10","title":"Monitoring","mono":"resolution of symptoms of clostridium difficile infection is indicative of efficacy.<br\/>"},"11":{"id":"929929-s-11","title":"How Supplied","mono":"<b>Dificid<\/b><br\/>Oral Tablet: 200 MG<br\/>"},"12":{"id":"929929-s-12","title":"Toxicology","sub":[{"id":"929929-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"929929-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"929929-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"929929-s-13","title":"Clinical Teaching","mono":"Drug may cause nausea, vomiting, abdominal pain, or gastrointestinal hemorrhage. <br\/>"}}}